Patient demographic background
Characteristics | Number or Mean (Range) | ||
|---|---|---|---|
| Index Group | Validation Group | ||
| No. of observations | 2141 | 397 | |
| No. of patients | 99 | 21 | |
| Observations per patient | 21.6 (6-61) | 18.9 (8-35) | |
| Age (yr) | 42.3 (16-66) | 42.1 (24-66) | |
| Height (cm) | 165.1 (148-184) | 166.3 (153-178) | |
| CBW (kg) | 57.9 (34-91) | 66.3 (44-86) | |
| BMI (kg/cm2) | 21.2 (14.5-33.3) | 22.4 (16.3-33.5) | |
| Sex (male/female) | 46/53 | 9/12 | |
| Dose (mg/12 h) | 25-275 | 50-260 | |
| Postoperative day | 47 (9-202) | 37 (12-95) | |
| INHI (Y/N)a | 1137/1004 | 175/222 | |
| TBIL (μM) | 11.2 (1.1-34.1) | 11.8 (4.4-39.6) | |
| ALT (U/1) | 30.1 (1-303) | 31.5 (3-293) | |
| ALP (U/1) | 61.5 (2-389) | 63.0 (2-380) | |
| γ-Glutamyl transferase (U/1) | 37.0 (2-394) | 37.1 (2-350) | |
| HCT (%) | 28.3 (10.9-49.3) | 28.5 (17.3-42.0) | |
| DRUG | |||
| Neoral | 75 | 18 | |
| Tianke | 22 | 3 | |
| Neocyspin | 7 | 0 | |
↵ a Account of concentrations concomitant with or without metabolic inhibitors of CsA.